Glipon MF Forte Tablet PR is a combination oral antihyperglycemic agent containing Metformin 1000 mg and Teneligliptin 20 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, thereby enhancing glucose uptake and utilization. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin levels, which inhibit glucagon release and increase insulin secretion in a glucose-dependent manner. The synergistic action of these agents effectively improves glycemic control by targeting multiple pathophysiological defects in type 2 diabetes. Glipon MF Forte Tablet PR is designed for prolonged release, ensuring sustained plasma concentrations and improved patient compliance. It is recommended as an adjunct to diet and exercise to improve glycemic parameters in adults inadequately controlled on monotherapy or lifestyle modifications alone. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of renal function and glycemic status is essential during therapy. Common adverse effects may include gastrointestinal disturbances and hypoglycemia, particularly when used with other antidiabetic agents. This combination therapy offers a convenient and effective option for comprehensive glycemic management in type 2 diabetes.